PRTK Insider Trading Activity and SEC Form 4 Filings
PRTK insider trading summary
No open-market insider purchases or sales of Paratek Pharmaceuticals, Inc. (PRTK) have been reported on SEC Form 4 in the past 12 months.
Latest PRTK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 9, 2023 | Michael Bigham | Exec. Chairman of the Board | Sell | $69K (31,250 @ $2.20) |
| Aug 9, 2023 | Randall B. Brenner | Chief Development & Regulatory | Sell | $61K (27,603 @ $2.20) |
| Aug 9, 2023 | William M. Haskel | CLO, General Counsel & Sec. | Sell | $76K (34,526 @ $2.20) |
| Aug 9, 2023 | Evan Loh | CEO | Sell | $108K (48,967 @ $2.20) |
| Mar 23, 2023 | James D Dondero | 10% Owner | Buy | $173K (100,000 @ $1.73) |
| Mar 22, 2023 | James D Dondero | 10% Owner | Buy | $188K (106,000 @ $1.77) |
| Mar 21, 2023 | James D Dondero | 10% Owner | Buy | $422K (242,500 @ $1.74) |
| Mar 20, 2023 | James D Dondero | 10% Owner | Buy | $147K (105,137 @ $1.40) |
| Mar 17, 2023 | James D Dondero | 10% Owner | Buy | $352K (234,863 @ $1.50) |
| Feb 21, 2023 | Jeffrey Stein | Director | Sell | $13K (7,000 @ $1.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.